Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alembic Nelarabine injection gets FDA final approval
Details : Nelarabine, generic version of Arranon injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia and lymphoma in adult & pediatric patients.
Brand Name : Arranon-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2024
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Eversana
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older.
Brand Name : Nelarabine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2023
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Eversana
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Cadila Gets 180-Day Exclusivity for Nelarabine Injection, Announces Final Approval From USFDA
Details : Nelarabine injection is generic version of Arranon®, granted competitive generic therapy (CGT) designation a chemotherapy drug that can be used to treat certain type of leukemia and lymphoma by slowing or stopping the growth of cancer cells.
Brand Name : Nelarabine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 18, 2021
Lead Product(s) : Nelarabine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?